Scarica l'app Stockscreener
8.89
18.93%
1.415
Dopo l'orario di chiusura:
8.96
0.07
+0.79%
Oric Pharmaceuticals Inc Borsa (ORIC) Ultime notizie
ORIC Pharmaceuticals stock nosedives 25% after hours: What is going on? - MSN
Beyond Meat posts downbeat Q4 results, joins RH, ORIC Pharmaceuticals and other big stocks moving lower in Wednesday's pre-market session - MSN
ORIC Pharma drops after early-stage trial data for prostate cancer therapy - MSN
ORIC Pharmaceuticals (ORIC) Is Down 28.2% After Selecting 400 mg Rinzimetostat Dose for Phase 3 - Sahm
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Sahm
ORIC Pharmaceuticals, Inc. (ORIC) stock price, news, quote and history - Yahoo Finance Australia
ORIC Pharmaceuticals Reports Inducement Grants - National Today
ORIC gives new employee 80,000 stock options and 15,000 RSUs - Stock Titan
ORIC Pharmaceuticals’ Global Ambitions amid Tumultuous Share Movements - StocksToTrade
Oric Pharmaceuticals (NASDAQ:ORIC) Trading 11.6% HigherTime to Buy? - MarketBeat
ORIC Pharmaceuticals Faces Turbulence Amid Prostate Cancer Drug Advancements - timothysykes.com
Investors Purchase Large Volume of Oric Pharmaceuticals Call Options (NASDAQ:ORIC) - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Diamedica Therapeutics (DMAC), Elevance Health (ELV) and Oric Pharmaceuticals (ORIC) - The Globe and Mail
Oric Pharmaceuticals (ORIC) Receives a Buy from Evercore ISI - The Globe and Mail
HC Wainwright Reiterates Buy Rating for ORIC, Maintains Price Ta - GuruFocus
HC Wainwright Reaffirms Buy Rating for Oric Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
Oric Pharmaceuticals stock falls on prostate cancer trial data, Sellside Comments - Investing.com Canada
H.C. Wainwright reiterates Buy on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Buy on ORIC Pharmaceuticals stock - Investing.com
Guggenheim Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC) - The Globe and Mail
HC Wainwright Reiterates Buy Rating for ORIC, Maintains Price Target | ORIC Stock News - GuruFocus
ORIC Stock Pullback Seen as Buying Opportunity - GuruFocus
ORIC Pharmaceuticals (ORIC) Is Down 36.1% After Advancing Lower-Toxicity Prostate Cancer Drug to Phase 3 - finance.yahoo.com
What's Behind The Drop In Oric Pharmaceuticals Stock Today? - Sahm
What's behind the drop in Oric Pharmaceuticals stock today? - MSN
ORIC: Opportunity Arises in Oric Pharmaceuticals Amid Price Drop - GuruFocus
ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses - Stocktwits
Wolfe Research reiterates Peerperform on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada
Pfizer (PFE) Competes in Prostate Cancer Treatment Landscape - GuruFocus
ORIC Pharmaceuticals: Updates Did Not Bode Well For This Valuation (NASDAQ:ORIC) - seekingalpha.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Oric Pharma Unveils Rinzimetostat Phase Ib Data And Outlines Phase III Study In Prostate Cancer - RTTNews
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Down Following Analyst Downgrade - MarketBeat
Oric Pharmaceuticals (ORIC) Sees Overreaction to Phase 1 Study D - GuruFocus
Oric Pharmaceuticals (NASDAQ:ORIC) Given New $17.00 Price Target at Wedbush - MarketBeat
Wedbush Lowers Price Target for ORIC Pharmaceuticals | ORIC Stoc - GuruFocus
Cantor Fitzgerald reiterates Overweight on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com
Beyond Meat Posts Downbeat Q4 Results, Joins RH, ORIC Pharmaceuticals And Other Big Stocks Moving Lower I - Benzinga
ORIC falls after hours on safety concerns around prostate cancer candidate at higher doses - MSN
ORIC Pharmaceuticals Stock Nosedives 25% After Hours: What Is Going On? - Benzinga
24H｜DEFT Soared 50%; NCino Surged 20%; Oric Pharmaceuticals Plunged 25%; Battalion Oil Down 9% - Tiger Brokers
Oric Advances Rinzimetostat Toward First Prostate Cancer Phase 3 - TipRanks
Transcript : ORIC Pharmaceuticals, Inc.Special Call - MarketScreener
ORIC Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile - bitget.com
ORIC's Rinzimetostat Shows Promise in Prostate Cancer Treatment - GuruFocus
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):